Adrian Gottschlich
Overview
Explore the profile of Adrian Gottschlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Seifert M, Benmebarek M, Briukhovetska D, Markl F, Dorr J, Cadilha B, et al.
Br J Cancer
. 2022 Oct;
127(12):2175-2185.
PMID: 36266575
Background: Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a...
12.
Demel U, Boger M, Yousefian S, Grunert C, Zhang L, Hotz P, et al.
J Clin Invest
. 2022 May;
132(9).
PMID: 35499080
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity...
13.
Kolorz J, Demir S, Gottschlich A, Beirith I, Ilmer M, Luthy D, et al.
Curr Oncol
. 2022 Jan;
29(1):94-110.
PMID: 35049682
Rhabdoid tumors (RT) are among the most aggressive tumors in early childhood. Overall survival remains poor, and treatment only effectively occurs at the cost of high toxicity and late adverse...
14.
Umut O, Gottschlich A, Endres S, Kobold S
Memo
. 2021 Nov;
14(2):143-149.
PMID: 34777609
Chimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is...
15.
Cadilha B, Benmebarek M, Dorman K, Oner A, Lorenzini T, Obeck H, et al.
Sci Adv
. 2021 Jun;
7(24).
PMID: 34108220
CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (T) cells suppress the immune response...
16.
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, et al.
Nat Biomed Eng
. 2021 Jun;
5(11):1246-1260.
PMID: 34083764
The efficacy of adoptive cell therapy for solid tumours is hampered by the poor accumulation of the transferred T cells in tumour tissue. Here, we show that forced expression of...
17.
Gottschlich A, Endres S, Kobold S
Cancers (Basel)
. 2021 Feb;
13(3).
PMID: 33530653
Since its discovery, interleukin-1 has been extensively studied in a wide range of medical fields. Besides carrying out vital physiological functions, it has been implicated with a pivotal role in...
18.
Benmebarek M, Cadilha B, Herrmann M, Lesch S, Schmitt S, Stoiber S, et al.
Leukemia
. 2021 Jan;
35(8):2243-2257.
PMID: 33414484
Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia...
19.
Eisenmesser E, Gottschlich A, Redzic J, Paukovich N, Nix J, Azam T, et al.
Proc Natl Acad Sci U S A
. 2019 Mar;
116(12):5514-5522.
PMID: 30819901
Interleukin-37 (IL-37), a member of the IL-1 family of cytokines, is a fundamental suppressor of innate and acquired immunities. Here, we used an integrative approach that combines biophysical, biochemical, and...
20.
Gottschlich A, Endres S, Kobold S
Transl Lung Cancer Res
. 2018 May;
7(Suppl 2):S160-S164.
PMID: 29780710
No abstract available.